Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid SCHEMBL5941874 | 0.97 | CYP3A4 (0.80) | CYP3A4REN | |
| SCHEMBL5941970 | 0.94 | CYP3A4 (0.75) | CYP3A4REN | |
| SCHEMBL5942269 | 0.92 | CYP3A4 (1.00) | CYP3A4REN | |
| Formic Acid SCHEMBL5941996 | 0.92 | CYP3A4 (0.72) | CYP3A4REN | |
| SCHEMBL5942194 | 0.90 | CYP3A4 (0.68) | CYP3A4REN | |
| SCHEMBL5941643 | 0.90 | CYP3A4 (0.68) | CYP3A4REN | |
| Formic Acid SCHEMBL5942098 | 0.89 | CYP3A4 (0.94) | CYP3A4REN | |
| SCHEMBL5942306 | 0.88 | CYP3A4 (0.67) | CYP3A4REN | |
| SCHEMBL5942169 | 0.88 | CYP3A4 (0.67) | CYP3A4REN | |
| SCHEMBL5942020 | 0.88 | CYP3A4 (0.73) | CYP3A4REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060009497-A1 | Novel tetrahydropyridine derivatives as renin inhibitors | ACTELION PHARMACEUTICALS, LTD. (CH) | 2006-01-12 | — | — | US | claimed |
| EP-1519920-A1 | NOVEL TETRAHYDROPYRIDINE DERIVATIVES AS RENIN INHIBITORS | Actelion Pharmaceuticals Ltd. (CH) | 2005-04-06 | — | — | EP | claimed |
| WO-2004002957-A1 | NOVEL TETRAHYDROPYRIDINE DERIVATIVES AS RENIN INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2004-01-08 | — | — | WO | claimed |
| WO-2008088690-A2 | A PROCESS FOR PREPARING DIAZABICYCLO[3.3.1] NONANE COMPOUNDS | MERCK & CO., INC. (US) | 2008-07-24 | — | — | WO | disclosed |
| US-20060009497-A1 | Novel tetrahydropyridine derivatives as renin inhibitors | ACTELION PHARMACEUTICALS, LTD. (CH) | 2006-01-12 | — | — | US | disclosed |
| EP-1519920-A1 | NOVEL TETRAHYDROPYRIDINE DERIVATIVES AS RENIN INHIBITORS | Actelion Pharmaceuticals Ltd. (CH) | 2005-04-06 | — | — | EP | disclosed |
| WO-2004002957-A1 | NOVEL TETRAHYDROPYRIDINE DERIVATIVES AS RENIN INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2004-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009497-A1 | Novel tetrahydropyridine derivatives as renin inhibitors | REN, ACE, ACE2 | CYP3A4 181/4885REN 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.